课题基金 / 基金详情

99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis

99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis
99mTc-DTB-Antifol-Pteroyls(RadioDAP):类风湿关节炎的治疗诊断
批准号:
7906159
负责人:
Joel R Morgan
金额:
$29.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-01 至 2012-08-31

项目摘要

项目成果

Joel R Morgan的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):风湿性关节炎(RA)在美国有2,100,000人发生,并与进行性关节破坏、功能残疾和预期寿命缩短相关。没有滑膜炎症就不会发生关节破坏。RA的治疗旨在抑制炎症,目的是建立缓解状态。现在有证据表明,尽管患者正在进行药物治疗,并且根据临床标准有明显的临床缓解,但仍会发生活动性亚临床滑膜炎和进行性关节破坏。这些数据表明,美国有超过1,500,000名患者存在持续关节破坏的风险。即使使用目前最有效的疾病缓解抗风湿药物(DMARDs),大多数患者也无法达到缓解。因此,即使亚临床滑膜炎可以被常规检测到,在大多数患者中完全根除关节炎症可能是不可行的,使用目前可用的DMARD治疗手段。因此,需要在诊断和治疗方法方面进行重大的范式转变。甲氨蝶呤(MTX)是治疗RA的首选药物,然而,它在约80%的患者中未能实现临床缓解,主要是因为(i)由于其狭窄的治疗指数而导致的剂量限制性毒性,以及(ii)不完全和高度可变的细胞摄取。为了提高患者临床和亚临床关节炎症的根除率,我们的目标是寻求一种改善现有金标准DMARD的策略。2006年,美国有3,969,000张MTX处方,预计新的抗叶酸剂DMARD标准的潜在影响将是重大的,可能影响数十万RA患者。我们建议开发和测试一系列新的治疗诊断99 mTc-DTB- Antifol-Pteroyls(RadioDAP),我们假设这将允许高度靶向和集中递送抗叶酸剂(例如氨基蝶呤,AMT)和99 mTc放射性核素到亚临床滑膜炎的部位,以通过SPECT成像进行治疗和诊断。我们的长期假设是,治疗性RadioDAP(i)将通过高度靶向和强烈地将抗叶酸剂递送到明显和亚临床滑膜炎症部位,显著增加RA的缓解率,(ii)将更早地检测亚临床滑膜炎,并具有更高的特异性,随着时间的推移进一步监测治疗反应的能力,并将个体患者的这种反应与药剂的递送相关联。SBIR拨款提案中为期两年的实验计划旨在通过使用体外叶酸转运模型为其化学组装和细胞吸收奠定初步基础,从而启动RadioDAP的开发。 公共卫生相关性:叙述性风湿性关节炎(RA)在美国有2,100,000人发生,并与进行性关节破坏、功能残疾和预期寿命缩短相关。拟议的RadioDAP技术将用于同时改善RA治疗和诊断。
英文摘要
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) occurs in 2,100,000 people in the United States, and is associated with progressive joint destruction, functional disability and decreased life expectancy. Joint destruction does not occur without synovial inflammation. The treatment of RA is directed to suppressing inflammation, with the aim of establishing a state of remission. There is now evidence that active subclinical synovitis and progressive joint destruction occurs in patients despite ongoing drug therapy and apparent clinical remission by clinical criteria. These data suggest that well over 1,500,000 patients in United States are at risk for continued joint destruction. Even with the most effective disease-modifying antirheumatic drugs (DMARDs) currently available, the majority of patients fail to achieve remission. Thus, even if subclinical synovitis could be routinely detected, completely eradicating joint inflammation in most patients is likely to be untenable using the currently available armamentarium of DMARDs. A major paradigm shift in diagnostic and therapeutic approach is therefore required. Methotrexate (MTX) is the drug of first choice in treating RA, however, it fails to achieve clinical remission in about 80% of patients mainly because of (i) dose-limiting toxicities due to its narrow therapeutic index, and (ii) incomplete and highly variable cellular uptake. To increase the rate of eradicating clinical and subclinical joint inflammation in patients, we aim to pursue a strategy that will improve on the existing goldstandard DMARD. With 3,969,000 prescriptions for MTX in the United States in 2006, the potential impact of a new antifolate DMARD standard would be expected to be major, potentially affecting hundreds of thousands of patients with RA. We propose to develop and test a series of novel theranostic 99mTc-DTB- Antifol-Pteroyls (RadioDAPs) that we hypothesize will allow the highly targeted and concentrated delivery of antifolate (e.g. aminopterin, AMT) and 99mTc radionuclide to sites of subclinical synovitis for treatment and diagnosis by SPECT imaging. Our long-term hypotheses are that a theranositic RadioDAP (i) will significantly increase the rate of remission in RA through highly targeted and intense delivery of antifolate to sites of overt and subclinical synovial inflammation, and (ii) will detect subclinical synovitis earlier and with greater specificity, with the further ability to monitor for response to therapy over time, and relate this response in an individual patient to delivery of the agent. The two-year experimental plan in this SBIR Grant proposal aims to jumpstart the development of RadioDAPs by laying the initial groundwork for their chemical assembly and cellular uptake using in vitro models of folate transport. PUBLIC HEALTH RELEVANCE: Narrative Rheumatoid arthritis (RA) occurs in 2,100,000 people in the United States, and is associated with progressive joint destruction, functional disability and decreased life expectancy. The proposed RadioDAP technology will be used to simultaneously improve RA therapy and diagnosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB
  • 批准号:
    8317529
  • 项目类别:
  • 资助金额:
    $28.07万
  • 财政年份:
    2011
  • 负责人:
    Joel R Morgan
  • 依托单位:
Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB
  • 批准号:
    8121904
  • 项目类别:
  • 资助金额:
    $27.1万
  • 财政年份:
    2011
  • 负责人:
    Joel R Morgan
  • 依托单位:
99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis
  • 批准号:
    8133718
  • 项目类别:
  • 资助金额:
    $29.51万
  • 财政年份:
    2010
  • 负责人:
    Joel R Morgan
  • 依托单位:
Snap-To-It Probes
  • 批准号:
    7940065
  • 项目类别:
  • 资助金额:
    $20.0万
  • 财政年份:
    2009
  • 负责人:
    Joel R Morgan
  • 依托单位:
海外基金